The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Evaluating the use of ctDNA as a biomarker in lung cancer
Bruna Pellini, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the emerging role of circulating tumor DNA (ctDNA) as a biomarker of progression in lung cancer. Findings from the Phase III EMPOWER-Lung 1 trial (NCT03088540) of cemiplimab monotherapy in patients with non-small cell lung cancer (NSCLC) concluded that treatment outcomes were reflected in differences in ctDNA levels. The Phase III IMpower131 trial (NCT02367794) of atezolizumab with platinum-based chemotherapy additionally demonstrated that ctDNA can stratify patients based on disease risk after three cycles of treatment. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
